Subcutaneous Unfractionated Heparin for Treatment of Venous Thromboembolism in End-Stage Renal Disease

Abstract

Objective:

To report 3 cases of venous thromboembolism (VTE) in patients with end-stage renal disease (ESRD) treated with subcutaneous unfractionated heparin (UFH) bridged with warfarin.

Case Summaries:

Three patients with ESRD were successfully treated for VTE with unmonitored, fixed-dose subcutaneous UFH every 12 hours and doseadjusted warfarin. The first patient was initiated on continuous infusion UFH for deep-vein thrombosis, but due to poor vascular access, nurses were unable to consistently measure anti-Xa levels. Therefore, subcutaneous UFH 17,500 units (~245 units/kg/dose) every 12 hours was initiated. Oral warfarin 5 mg/day was started the following day. The patient received 4 days of inpatient subcutaneous UFH and then was discharged to complete the bridge as an outpatient. The second patient received subcutaneous UFH 10,000 units (~244 units/kg/dose) every 12 hours and oral warfarin 2.5 mg/day to treat a nonocclusive thrombus along her right femoral vein hemodialysis catheter. The patient received 1 day of inpatient subcutaneous UFH treatment prior to discharge and continued bridge therapy with warfarin as an outpatient. The third patient was initiated on subcutaneous UFH 20,000 units (~223 units/kg/dose) every 12 hours and oral warfarin 7.5 mg/day due to a subtherapeutic INR (1.50) 5 days after receiving fresh frozen plasma to reduce her therapeutic INR for a procedure. The patient received 2 doses of subcutaneous UFH as an inpatient before treatment was discontinued because her INR was therapeutic at 2.3.

Discussion:

Subcutaneous UFH has been used to treat VTE since the early 1980s; however, with the advent of low-molecular-weight heparin (LMWH), subcutaneous UFH use diminished. Several studies comparing the use of subcutaneous UFH to both continuous infusion UFH and LMWH concluded that subcutaneous UFH is a safe and efficacious alternative. The 2008 Chest Guidelines for Antithrombotic Therapy for Venous Thromboembolic Disease support the use of subcutaneous UFH for the treatment of VTE with a Grade 1A recommendation and provide a Grade 2C recommendation for use of UFH over LMWH for patients with VTE and severe renal failure.

Conclusions:

Safe and convenient treatment options for VTE in patients with ESRD are limited. Fixed-dose, unmonitored subcutaneous UFH as a bridge to warfarin therapy is an effective option in patients with ESRD and those with financial restrictions. The pharmacist plays a key role in identifying patients for whom subcutaneous UFH treatment may be a viable alternative, recommending an appropriate dosing regimen, and educating health-care professionals and patients about safe use.

Keywords

deep-vein thrombosis end-stage renal disease pulmonary embolism subcutaneous unfractionated heparin venous thromboembolism treatment

Get full access to this article

View all access options for this article.

References

Kearon

, Kahn

, Agnelli

, Goldhaber

, Raskob

, Comerota

. Antithrombotic therapy for venous thromboembolic disease: the eighth ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2008; 133:454S–545S. DOI 10.1378/chest. 08-0685

Hommes

, Bura

, Mazzolai

, Büller

, ten Cate

. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. Ann Intern Med 1992; 116:279–84.

Product information. Lovenox (enoxaparin). Bridgewater, NJ: Sanofiaventis, December 2009.

Nutescu

, Spinier

, Wittkowsky

, Dager

. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 2009; 43:1064–83. DOI 10.1345/aph.1L194

Levey

, Coresh

, Balk

. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139:137–47.

Prandoni

, Carnovali

, Marchiori

. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Arch Intern Med 2004; 164:1077–83.

Kearon

, Ginsberg

, Julian

. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 2006; 296:935–42.

The Joint Commission. High-alert medications and patient safety. www.jointcommission.org/SentinelEvents/SentinelEventAlert/sea_11.htm (accessed 2010 Aug 9).

The Joint Commission. Preventing errors related to commonly used anticoagulants. www.jointcommission.org/SentinelEvents/SentinelEventAlert/sea_41.htm (accessed 2010 Aug 9).